Liver Metastases Treatment Market By Treatment Type (Surgical Resection, Thermal Ablation, Embolization & Radioembolization, Chemotherapy, Targeted Therapy, Immunotherapy, Hepatic Perfusion, Histotripsy, Liver Transplantation, Radiation Therapy/SBRT), By Primary Cancer Origin (Colorectal Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, Melanoma/Uveal Melanoma, Neuroendocrine Tumors, Other Primary Cancers), By End User (Hospitals, Comprehensive Cancer Centers, Specialty Oncology & Interventional Radiology Centers, Academic & Research Institutions), By Geography, Segment Revenue Estimation, Forecast: 2026–2032

Liver Metastases Treatment Market: Local Control, Biomarker-Directed Therapy, and New Liver-Directed Platforms Reshape Treatment

The Global Liver Metastases Treatment Market was valued at an estimated USD 3.28 billion in 2025 and is projected to reach USD 6.00 billion by 2032, expanding at a CAGR of 9.0% during 2026–2032, according to Strategic Market Research.

 

The liver metastases treatment market is shifting from a predominantly systemic-therapy model toward a more integrated treatment pathway combining oncology drugs, surgery, thermal ablation, embolization, hepatic-directed drug delivery, and emerging non-invasive technologies. Treatment for liver metastasis depends on the primary cancer origin, number and size of tumors, and overall health. Options include surgical resection, localized ablation (heat or cold), embolization (TACE), systemic chemotherapy, targeted therapy, and immunotherapy. The main goal is controlling cancer growth and maintaining quality of life.

 

FDA-approved systemic therapies span multiple mechanisms of action including immune checkpoint inhibitors (PD-1/PD-L1 and CTLA-4), anti-VEGF agents, EGFR inhibitors, BRAF/MEK pathway inhibitors, HER2-targeted therapies, and multikinase tyrosine kinase inhibitors, reflecting the molecular stratification of metastatic disease. Systemic therapy is selected primarily according to the biology of the originating cancer, while liver-directed treatment depends on whether disease is confined or predominantly limited to the liver, the number and location of lesions, technical resectability, response to systemic therapy, liver reserve, and availability of specialist expertise.

 

The underlying patient pool is substantial and clinically diverse. A recent SEER analysis covering 4.18 million patients diagnosed with cancer between 2010 and 2021 identified 249,946 patients, or 6.0%, with synchronous liver metastases. Colorectal cancer accounted for approximately 25% of these cases, followed by lung cancer at 24% and pancreatic cancer at 21%. The absolute number of patients presenting with liver metastases increased over the study period even though trends differed substantially by primary tumor.

 

Resectability Remains the Most Important Treatment Divide

Surgical resection continues to provide the strongest curative-intent pathway for appropriately selected patients, particularly those with colorectal liver metastases. The National Cancer Institute notes that selected patients undergoing resection of liver metastases can achieve 5-year cure rates exceeding 20%, a major distinction from treatment given only for disease control.

However, surgical eligibility remains far narrower than the total metastatic population. A 2025 SEER-Medicare study evaluated 34,781 patients aged 66–85 years with liver-isolated colorectal metastases between 2000 and 2020. Only 10.9% received curative-intent liver-directed treatment. Among those treated, 74.3% underwent hepatectomy, while 24.9% received ablation alone and fewer than 1% underwent transplantation. The analysis also found substantial geographic variation in access. Every five-percentage-point increase in local use of curative-intent liver therapy was associated with improved risk-adjusted survival.

For the market, this treatment gap creates a larger opportunity than procedure growth alone suggests. Increased referral to hepatobiliary multidisciplinary teams can move patients from chemotherapy-only pathways into surgery, ablation, combined local-systemic therapy, or other liver-directed procedures. Access to surgeons with liver-specific expertise remains uneven, making specialist-center capacity and referral networks material constraints on procedure volumes.

The surgical segment is also changing operationally. Treatment increasingly includes staged resections, simultaneous colorectal and liver procedures, liver-first strategies, preoperative systemic therapy, and repeat intervention for recurrent disease rather than a single definitive operation. Population-based evidence from England shows considerable variation in how synchronous colorectal primary tumors and liver metastases are sequenced, reflecting greater use of individualized multidisciplinary treatment plans.

 

Thermal Ablation Is Moving Closer to Surgery for Small Liver Metastases

Thermal ablation has historically filled the gap for patients who could not undergo resection or whose tumors were small enough to be destroyed while preserving healthy liver tissue. New randomized evidence is strengthening its position beyond that traditional role.

The COLLISION phase III trial randomized approximately 300 patients with up to ten colorectal liver metastases measuring no more than 3 cm to surgical resection or thermal ablation. The study was stopped early after predefined evidence supported non-inferiority for overall survival. Thermal ablation also produced substantially fewer serious adverse events: approximately 7% compared with 20% after surgery. Median hospital stay was about one day for ablation versus four days for resection.

These findings have direct market consequences. Small, technically accessible lesions no longer automatically translate into an operating-room procedure. Percutaneous microwave or radiofrequency ablation can compete for a portion of patients previously referred for limited liver resection, especially when preservation of liver tissue, repeatability, shorter hospitalization, and faster recovery are priorities.

Microwave ablation has become particularly important within this segment because it can create larger treatment zones rapidly and is less affected than radiofrequency energy by blood-flow-related cooling near vessels. NICE already recognizes local ablative treatment as part of the curative-intent pathway for selected colorectal liver metastases and notes that microwave techniques have increasingly replaced older radiofrequency approaches in clinical practice.

The revenue opportunity therefore extends beyond disposable ablation probes. Growth in ablation volumes supports demand for image guidance, navigation, treatment-planning software, interventional imaging suites, anesthesia services, and repeat procedures when new lesions develop. The strongest near-term expansion is likely to remain concentrated in patients with relatively small tumors where complete local treatment can be achieved reliably.

 

Embolization Retains an Important but More Selective Position

Arterial therapies remain relevant for unresectable or liver-dominant disease, particularly when surgery and ablation cannot adequately treat the entire tumor burden. The category includes transarterial chemoembolization, bland embolization, and yttrium-90 selective internal radiation therapy.

Regulatory availability does not necessarily translate into unrestricted treatment use. FDA-authorized SIR-Spheres Y-90 microspheres include an indication for unresectable metastatic liver tumors from primary colorectal cancer in conjunction with intrahepatic arterial chemotherapy.

NICE takes a restrictive stance on selective internal radiation therapy (SIRT) for colorectal liver metastases, not recommending it as routine first-line treatment for patients unsuitable for curative local therapy, and limiting its use in chemotherapy-eligible patients to research settings while allowing carefully governed use in chemotherapy-intolerant or refractory cases, largely due to randomized evidence showing no clear overall-survival benefit when added to first-line systemic chemotherapy. As a result, radioembolization is positioned as a selective, niche intervention rather than a broad substitute for systemic therapy, with its strongest clinical and commercial role in liver-dominant disease where systemic options are limited or where targeted local control may still provide meaningful therapeutic benefit.

 

Systemic Therapy Remains the Largest Clinical Backbone, but Biomarkers Are Fragmenting Drug Use

The pharmacologic component of the liver metastases market cannot be assessed independently of the primary cancer. Colorectal, breast, lung, pancreatic, melanoma, and neuroendocrine liver metastases follow different systemic treatment pathways. Consequently, growth is increasingly determined by molecular subgroups rather than by liver involvement alone.

Metastatic colorectal cancer illustrates the change. FDA-approved treatment options now include immune checkpoint inhibitors for MSI-H/dMMR tumors and targeted combinations for molecularly selected disease. Pembrolizumab has been approved for first-line unresectable or metastatic MSI-H/dMMR colorectal cancer since 2020. In April 2025, the FDA approved nivolumab plus ipilimumab for unresectable or metastatic MSI-H/dMMR colorectal cancer based on CheckMate-8HW.

The FDA has also approved tucatinib plus trastuzumab for previously treated HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer. These approvals demonstrate why molecular testing has become an economically important part of advanced metastatic cancer care: drug eligibility increasingly depends on MSI/MMR status, RAS status, HER2 amplification, BRAF alterations, and other tumor-specific biomarkers rather than an anatomical diagnosis of liver metastasis.

Systemic treatment also influences revenue elsewhere in the treatment pathway. Tumor shrinkage can convert selected patients from unresectable to potentially resectable disease. Conversely, progression after several systemic lines can shift patients toward ablation, hepatic perfusion, radioembolization, clinical trials, or supportive treatment. Pharmaceutical and liver-directed procedure markets therefore overlap rather than operate independently.

 

HEPZATO Demonstrates the Commercial Potential of Organ-Directed Drug Delivery

One of the clearest examples of a dedicated liver-metastasis commercial platform is Delcath Systems' HEPZATO KIT, approved by the FDA in August 2023 for adults with uveal melanoma and unresectable hepatic metastases affecting less than 50% of the liver, with no extrahepatic disease or only limited extrahepatic disease meeting specified criteria. The system delivers high-dose melphalan directly to the liver while filtering the drug from the blood before it returns to systemic circulation.

Although metastatic uveal melanoma represents a relatively specialized patient population, commercialization provides useful evidence of what a liver-directed platform can achieve when a clearly defined treatment gap, regulatory indication, procedural infrastructure, and specialist-center network are aligned.

Delcath reported USD 85.2 million in total 2025 revenue, including USD 78.8 million from HEPZATO, with 28 active U.S. treatment centers at year-end. HEPZATO procedure volume increased approximately 140% compared with 2024, according to the company's 2025 results.

Commercial momentum continued into 2026. On August 6, 2026, Delcath reported second-quarter revenue of USD 29.1 million, compared with USD 24.2 million a year earlier. HEPZATO contributed USD 27.1 million, and the active-center network had increased to 31 centers. The company reported approximately 30% year-over-year procedure-volume growth during the quarter and raised its 2026 revenue outlook to USD 104–108 million. These are company-reported figures, but they provide a direct measure of adoption rather than a modeled market estimate.

Delcath is also investigating hepatic perfusion outside uveal melanoma. A global phase II study combining HEPZATO with standard therapy has begun enrolling patients with liver-dominant HER2-negative metastatic breast cancer, while colorectal and other liver-dominant indications remain areas of clinical development. Successful expansion would materially increase the addressable population because the platform could move from a rare-cancer niche toward larger metastatic indications.

 

Histotripsy Is Creating a New Non-Invasive Ablation Category

Histotripsy represents a different competitive threat to conventional liver-directed procedures because it mechanically destroys targeted tissue using focused ultrasound rather than needles, heat, ionizing radiation, or surgical excision.

The FDA granted De Novo authorization to the HistoSonics Edison Histotripsy System in October 2023 for non-invasive destruction of liver tumors through non-thermal mechanical tissue ablation. The regulatory indication concerns tissue destruction; the FDA clearance should not be interpreted as proof of improved cancer survival.

Early clinical performance has nevertheless attracted considerable interest, with early reports indicating high technical success in tumor targeting and a relatively low rate of major procedure-related complications within the first 30 days.

The platform's geographic reach expanded in 2026. HistoSonics received a European CE Mark in July 2026, with a phased rollout planned through selected European centers. Twelve-month follow-up data reported 90% local tumor control across treated tumors and one-year overall survival of 48.6% among patients with metastatic disease, although longer follow-up and comparative evidence remain necessary before survival advantages can be attributed to histotripsy itself.

Investor interest also reflects the perceived platform opportunity. A transaction announced in 2025 valued HistoSonics at approximately USD 2.25 billion, providing a rare observable valuation signal for an emerging liver-treatment device platform.

Reimbursement is now one of the main determinants of how rapidly histotripsy can move from specialized centers into routine practice. Anthem's 2026 medical policy considers histotripsy medically necessary only under specified conditions, including primary or metastatic liver tumors where other therapies are unavailable, inadequate or inappropriate, with tumors generally limited to 3 cm or less and three or fewer lesions. Use outside the policy criteria is considered investigational and not medically necessary.

The technology therefore has regulatory momentum but still faces a narrower reimbursable population than its technical capability may eventually support. Additional comparative studies, expanded payer coverage, treatment-center installation, operator training, and evidence in larger or anatomically difficult lesions will determine how much volume it captures from thermal ablation, radiation, and surgery.

 

Liver Transplantation Is Opening a Highly Selected Curative-Intent Pathway

Liver transplantation for colorectal liver metastases was historically considered impractical because of recurrence risk and limited donor organs. The TransMet randomized trial has materially changed the evidence base for a carefully selected subgroup.

The trial enrolled 94 patients with permanently unresectable, liver-only colorectal metastases whose disease remained controlled by chemotherapy and met strict biological selection criteria. In the intention-to-treat population, 5-year overall survival was 56.6% with liver transplantation plus chemotherapy versus 12.6% with chemotherapy alone. In the per-protocol analysis, survival was 73.3% versus 9.3%, respectively.

The treatment will remain capacity-constrained. Transplantation requires stringent patient selection, organ availability, specialized surgical infrastructure, lifelong immunosuppression, and extensive follow-up. Its importance to the market lies less in immediate procedure volume than in extending the definition of potentially curative liver-directed treatment.

The change is already appearing in mainstream clinical references. The NCI's colorectal cancer treatment information now includes total hepatectomy followed by liver transplantation among potential approaches for selected patients whose liver metastases cannot otherwise be surgically removed.

 

Market Growth Will Depend More on Treatment Conversion Than on One New Therapy

The biggest opportunity in treating liver metastases is making sure more patients actually reach the right kind of liver-focused treatments. Right now, many patients who could benefit from specialized procedures are still only receiving general drug therapy. This means there is a clear gap between what is medically possible and what is actually being done in practice.

At the same time, treatment options are improving and becoming less invasive. For example, newer studies show that ablation (a technique that destroys tumors using heat or energy) can work almost as well as surgery for small liver tumors in some colorectal cancer patients. Even more recently, a new method called histotripsy is emerging, which can destroy tumors without surgery or incisions. Another approach, hepatic perfusion, is helping build specialized treatment centers that focus only on delivering therapy directly to the liver, showing that these advanced technologies can also be commercially successful.

Overall, the market is expanding due to five key trends. More patients are being referred to liver specialists, increasing access to surgery and ablation instead of chemotherapy alone. Minimally invasive treatments are also gaining wider acceptance as clinical evidence continues to support their effectiveness. In addition, repeat liver treatments are becoming more common because newer techniques better preserve healthy liver tissue. Cancer care is also becoming more personalized, with genetic and biomarker testing guiding the use of targeted therapies and immunotherapy, particularly in colorectal cancer. Finally, newer platform technologies such as histotripsy and hepatic perfusion may expand into broader cancer indications as clinical data and reimbursement support grow.

However, there are still important limitations. Not all patients are suitable for these treatments because it depends on the type of cancer and how it has spread. Advanced liver procedures are also mostly available only in large, specialized hospitals. Some treatments, like radioembolization, are only recommended in certain cases by medical guidelines. Newer technologies such as histotripsy are still limited by insurance approval rules, and liver transplants are restricted by the shortage of available donor organs.

 

Regional Analysis: Treatment Access and Technology Adoption Create Distinct Growth Patterns

North America accounts for approximately 38–42% of the global liver metastases treatment market share, supported by advanced oncology infrastructure and early adoption of interventional and surgical liver-directed therapies. Based on the global market size of USD 3.28 billion in 2025, the regional market is estimated at approximately USD 1.25–1.38 billion in 2025. The region is projected to grow at a CAGR of around 8.5–9.2% during 2026–2032, broadly aligned with the global growth trajectory, driven by increasing utilization of ablation, radioembolization, and biomarker-driven systemic therapies.

The U.S. leads early adoption of new liver metastases treatments. HEPZATO is FDA-approved for unresectable hepatic metastases from uveal melanoma, while the Edison Histotripsy System has FDA De Novo authorization for non-invasive liver tumor destruction. Delcath reported 31 active HEPZATO centers in Q2 2026, with USD 27.1 million in quarterly revenue and about 30% year-over-year growth in procedures, highlighting strong early clinical uptake.

Europe is a key liver metastases treatment region, supported by a large colorectal cancer burden and strong oncology infrastructure. IARC estimated 527,533 new colorectal cancer cases in 2024, making it the second most common cancer in Europe (12.2% of all cases). While this reflects primary cancer, it highlights the large pool of patients at risk of liver metastases.

Europe accounts for an estimated ~28–30% share of the global liver metastases treatment market (~USD 0.92–0.98 billion in 2025), with expected growth of ~8.2–8.6% CAGR through 2032, driven by wider use of minimally invasive ablation, targeted therapies, and interventional oncology.

Adoption is strongly influenced by strict reimbursement and health-technology assessment systems, which can slow uptake but support stable, evidence-based use once approved. A key development is the 2026 European CE Mark for HistoSonics’ histotripsy system, enabling non-invasive liver tumor treatment to begin phased rollout in specialist centers.

Asia-Pacific represents the largest patient pool for liver metastases treatment, driven by a high colorectal cancer burden. IARC 2024 data shows about 1.06 million new colorectal cancer cases in Asia, accounting for over half of the global total (~2.04 million cases). While this does not directly equal liver metastases cases, it highlights a strong pipeline of patients likely to develop metastatic disease requiring liver-directed care.

From a market perspective, Asia-Pacific is estimated to account for ~32% of the global liver metastases treatment market in 2025, supported by expanding oncology infrastructure and growing use of minimally invasive procedures. The region is expected to grow at a CAGR of ~10.2% (2026–2032), reaching about USD 1.92 billion by 2032, with growth concentrated in China, Japan, and India as access to systemic therapies, interventional oncology, and reimbursement improves. However, adoption remains uneven, with advanced treatments largely concentrated in major tertiary hospitals, while broader expansion depends on improved specialist access and healthcare funding.

Overall, regional market development will depend less on differences in disease biology and more on how frequently eligible patients reach specialist liver teams and how quickly healthcare systems reimburse new local treatments. North America currently offers favorable conditions for early commercialization, Europe combines a large treated population with stricter evidence-based adoption, while Asia-Pacific provides the largest long-term patient-volume opportunity.

 

Competitive Landscape: Shift Toward Multimodal and Sequential Liver-Directed Treatment Strategies

The liver metastases treatment market is supported by a diverse set of companies spanning systemic drug delivery, liver-directed perfusion, ablation technologies, radiation therapy, embolization systems, and surgical oncology tools. Together, these players define a multimodal ecosystem where treatment selection depends on tumor biology, resectability, and disease distribution.

Delcath Systems has established the first commercially scaled hepatic perfusion platform with its HEPZATO KIT (melphalan-based liver-directed chemotherapy). It is currently approved for unresectable hepatic metastases from uveal melanoma and is expanding into metastatic breast and colorectal liver-dominant disease, positioning it as a niche but high-impact organ-specific drug delivery platform.

HistoSonics is introducing a new non-invasive treatment category with its Edison Histotripsy System, which uses focused ultrasound to mechanically destroy liver tumors. With FDA De Novo authorization, it competes directly with thermal ablation, surgery, and radiation, and represents a potential shift toward incisionless tumor destruction.

In the interventional oncology space, Boston Scientific (via TheraSphere) and Sirtex Medical (SIR-Spheres, part of Varian/Siemens Healthineers) are the dominant players in radioembolization. Both provide Y-90 microsphere-based selective internal radiation therapy for hepatocellular carcinoma and metastatic liver disease, particularly colorectal liver metastases, forming the backbone of transarterial radiation-based treatment.

Medtronic maintains a strong position in thermal ablation through microwave (Emprint) and radiofrequency ablation systems, widely used for primary and metastatic liver tumors. These technologies remain central to minimally invasive local tumor destruction in interventional radiology and surgical oncology.

In surgical oncology, Johnson & Johnson (Ethicon and Biosense Webster ecosystem) supports liver metastasectomy through advanced surgical instruments, energy devices, and navigation systems, enabling curative-intent resections and complex abdominal procedures.

Varian (Siemens Healthineers) plays a key role in non-invasive external beam radiation therapy, particularly stereotactic body radiotherapy (SBRT) systems like TrueBeam, which are used for oligometastatic and unresectable liver lesions where surgery or ablation is not feasible.

Finally, Terumo/BTG (now part of Boston Scientific) provides essential interventional infrastructure, including embolic agents and microcatheters, enabling transarterial embolization and chemoembolization procedures that support liver-directed therapy across metastatic disease and hepatocellular carcinoma.

 

Market Outlook

Analyst Perspective views the 9.0% CAGR (2026–2032) as being driven mainly by more treatment steps per patient, not just rising disease cases. Patients with liver metastases often now receive multiple sequential therapies, including systemic drugs, molecular testing, surgery or ablation, and in some cases newer options like histotripsy or hepatic perfusion—creating multiple revenue-generating procedures per patient.

The biggest near-term change is in small, treatable liver metastases, where studies show thermal ablation can match surgery in selected colorectal cases, while histotripsy adds a non-invasive option. This is not reducing surgery overall but shifting how individual lesions are treated based on size, location, and patient condition.

A key commercial example is Delcath’s HEPZATO, which generated USD 27.1 million in Q2 2026 revenue with 31 treatment centers and about 30% year-over-year growth in procedures. This shows that even narrow liver-directed therapies can scale when concentrated in specialist centers, with potential upside if expanded into larger metastatic populations like breast or colorectal cancer.

Histotripsy has regulatory approval in the U.S. and a 2026 EU CE Mark, but growth will depend on reimbursement and stronger clinical evidence, not just approvals. If adopted more widely, it could sit alongside ablation, radioembolization, SBRT, and surgery as a standard liver-directed option.

From a demand perspective, colorectal cancer remains a major driver, with about 2.04 million global cases in 2024, including ~1.06 million in Asia and ~527,533 in Europe (IARC). These figures highlight where future liver metastasis treatment demand is likely to emerge as access improves.

Overall, the strongest market position will come from technologies that fit into a multi-step treatment pathway—used before surgery, instead of surgery in selected cases, after systemic therapy, or repeatedly for recurrence. Solutions that are repeatable, liver-sparing, and well reimbursed across specialist centers are best placed to benefit from growth toward USD 6.00 billion by 2032.

Strategic Market Research expects the fundamental market shift to be from “treating metastatic disease systemically” toward “actively managing liver disease over multiple treatment stages.” That change expands the role of interventional oncology and creates revenue opportunities across pharmaceuticals, procedure-based therapies, ablation platforms, imaging, treatment planning, and specialized liver-directed systems rather than concentrating growth in a single drug or device category.

 

Liver Metastases Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.28 Billion
Revenue Forecast in 2032	USD 6.00 Billion
Overall Growth Rate	CAGR of 9.0% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Primary Cancer Origin, By End User, By Geography
By Treatment Type	Surgical Resection, Thermal Ablation, Embolization & Radioembolization, Chemotherapy, Targeted Therapy, Immunotherapy, Hepatic Perfusion, Histotripsy, Liver Transplantation, Radiation Therapy/SBRT
By Primary Cancer Origin	Colorectal Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, Melanoma/Uveal Melanoma, Neuroendocrine Tumors, Other Primary Cancers
By End User	Hospitals, Comprehensive Cancer Centers, Specialty Oncology & Interventional Radiology Centers, Academic & Research Institutions
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising incidence of metastatic cancers, increasing adoption of liver-directed therapies, growth of biomarker-guided oncology treatments, expansion of minimally invasive ablation procedures, development of hepatic perfusion and non-invasive tumor destruction platforms
Customization Option	Available upon request